A huge battle has been won in the war against cancer, and the general behind this victory is a scientist working right here in Edmonton.
From inside the labs at the University of Alberta Dr. Lu Deng developed a test that’s being marketed in the US under the name PolypDX. It’s a urine test that screens for precancerous colorectal polyps.
Dr. Deng tells Global News that colorectal cancer is the third most common cancer that leads to death in both men and women.
“More than 200000 cases are diagnosed each year in North America. With the implementation of our test, we think that colorectal cancer can be totally prevented.”
Not only is PolypDX inexpensive, it’s also far more sensitive than the existing fecal test which screens for cancer. Dr. Deng’s test screens for metabolite markers that indicate pre-cancerous polyps which can be surgically removed, preventing cancer from developing.
For her groundbreaking work Dr. Deng has been awarded the prestigious Mitacs & NCR-IRAP Award for Commercialization. The award is presented to a Mitacs intern who has made a significant achievement in research and development innovation which makes it to market.